(2E,4E,6Z)-3-Methyl-7-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-3-propoxy-3-naphthalenyl)-2,4,6-octatrienoicacid

LG 100754 is a ligand of retinoid X receptor (RXR) that modulates the activity of RXR dimers. It acts as an antagonist towards RXR homodimers but as an agonist of heterodimers consisting of RXR and retinoic acid receptor (RAR) or PPARs. LG 100754, at 1 μM, is a weak agonist of RXR-PPARγ but strongly enhances signaling through the heterodimer in response to PPARγ ligands, including rosiglitazone and 15-deoxy-Δ^12,14-prostaglandin J₂ . Through this action, LG 100754 decreases glucose levels and relieves insulin resistance in mice.

LG 100754 is a novel RXR:PPARγ agonist and decreases glucose levels in vivo. It can also be used in compositions comprising anti-androgen and anti-thyroid agents and kits for diagnosis and treatment of viral respiratory infection.